Polypeptides and methods of use
View Patent ↗Described herein are fragments of fibronectin and vitronectin and variants thereof that have certain activities, including growth factor-binding activity. Also described are fragments of growth factors that bind to fibronectin and inhibit binding of full-length growth factors to fibronectin. Compositions containing such fragments are useful in cosmetic treatments (e.g., the treatment of wrinkles or UV photodamage of skin), and the treatment of wounds and cancer.
1. An isolated polypeptide consisting of the sequence: PSHISKYILRWRPK (SEQ ID NO:9), PSLAKKQRFRHRNR (SEQ ID NO:10), or ISKYILRWRPK (SEQ ID NO:41).
2. A physiologically acceptable composition comprising the isolated polypeptide of claim 1 .
3. The physiologically acceptable composition of claim 2 , wherein the composition is formulated for topical administration.
4. A method of treating a patient who has a wound, the method comprising administering to the patient a therapeutically effective amount of the physiologically acceptable composition of claim 2 .
5. The method of claim 4 , wherein the wound is a surgical incision or extirpation, a traumatic injury, a burn, a lesion, or an ulceration of the patient's skin, mucosa, connective tissue, fascia, ligament, tendon, cartilage, nerve or muscle or a wound to the patient's bone.
6. The method of claim 5 , wherein the wound is a burn.
7. An isolated, cyclized polypeptide consisting of the sequence: CPSHISKYILRWRPKC (SEQ ID NO:82), CPSLAKKQRFRHRNRC (SEQ ID NO:83), or CISKYILRWRPKC (SEQ ID NO:84).
8. A physiologically acceptable composition comprising the isolated polypeptide of claim 7 .
9. The physiologically acceptable composition of claim 8 , wherein the composition is formulated for topical administration.
10. A method of treating a patient who has a wound, the method comprising administering to the patient a therapeutically effective amount of the physiologically acceptable composition of claim 9 .
11. The method of claim 10 , wherein the wound is a surgical incision or extirpation, a traumatic injury, a burn, a lesion, or an ulceration of the patient's skin, mucosa, connective tissue, fascia, ligament, tendon, cartilage, nerve or muscle or a wound to the patient's bone.
12. The method of claim 11 , wherein the wound is a burn.
13. An isolated, cyclized polypeptide of claim 7 , wherein the polypeptide consists of the sequence PSHISKYILRWRPK (SEQ ID NO:9)
14. A physiologically acceptable composition comprising the isolated polypeptide of claim 13 .
15. The physiologically acceptable composition of claim 14 , wherein the composition is formulated for intravenous administration.
16. A method of treating a patient who has a wound, the method comprising administering to the patient a therapeutically effective amount of the physiologically acceptable composition of claim 15 .
17. The method of claim 16 wherein the wound is a surgical incision or extirpation, a traumatic injury, a burn, a lesion, or an ulceration of the patient's skin, mucosa, connective tissue, fascia, ligament, tendon, cartilage, nerve or muscle or a wound to the patient's bone.
18. The method of claim 17 , wherein the wound is a burn.